Business
Hemostemix Announces Injunction Hearing Against Aspire Health Science, LLC
Calgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces Injunction Hearing Against Aspire Health Science, LLCCalgary, Alberta--(Newsfile Corp. - June 3, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (\"Hemostemix\" or the \"Company\") is pleased to announce that it has retained DLA Piper, a global law firm, and filed for an injunction against Aspire Health Science, LLC, for the return of the Company's property. A hearing for the injunction is set for June 18, 2020 at 10:00 MDT before the Court of Queen's Bench, Alberta. Equally, the Company is pleased to announce DLA Piper filed an amended motion to dismiss the Aspire Health Science, LLC Complaint in the Complex Business Litigation Court of the Ninth Judicial Circuit, in and for Orange County, Florida. ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract entitled \"Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup\" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years. The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit www.hemostemix.com. Contact: Thomas Smeenk, President, CEO & [email protected] 905-580-4170Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking Information: This news release contains \"forwar...